Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Up 20.0 %

NAVB stock opened at $0.00 on Tuesday. Navidea Biopharmaceuticals has a one year low of $0.00 and a one year high of $0.13.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.